FREMONT, Calif. and OXFORD, England, May 11, 2018 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysm, today announced the promotion of Stephen Griffin, PhD, […]
Author: Ken Dropiewski
BioCardia, Inc. Reports First Quarter 2018 Financial Results And Business Highlights
SAN CARLOS, Calif., May 11, 2018 /PRNewswire/ — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, filed its 10-Q for the three months ended March 31, 2018 with the Securities and Exchange Commission. First Quarter 2018 Financial Results: BioCardia reported a net loss of $3.6 million for the first quarter […]
Vesper Medical Completes $10.5 M Series A Financing to Drive Development of Next Generation Venous Stents
WAYNE, Pa.–(BUSINESS WIRE)–Vesper Medical, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that it completed its Series A financing totaling $10.5 million. Major participants in the Series A financing included New Enterprise Associates and Quaker Partners. The financing occurred in two tranches and is […]
New Scientia Vascular Product Facilitates Stroke Treatment
WEST VALLEY CITY, Utah–(BUSINESS WIRE)–Scientia Vascular, an early stage medical device company with patented and proprietary vascular access technology, recently received FDA clearance for a new product called the Aristotle 14 guidewire, which is used during ischemic and hemorrhagic strokes and other challenging interventional procedures. The Aristotle guidewire improves access […]
Stryker’s Trevo™ Retriever becomes first and only device indicated for acute ischemic stroke treatment up to 24 hours in Europe
KALAMAZOO, Michigan, USA, May 7, 2018 /PRNewswire/ — Following the expanded indication in the United States by the Food and Drug Administration (FDA) in February, Stryker’s Trevo Retriever has received CE marking as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, increasing the treatment window by 18 […]
REVA to Hold Annual General Meeting of Stockholders
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold its 2018 Annual General Meeting of Stockholders (the “AGM”) on Wednesday, May 16, 2018 at 4:00 p.m. US PDT (which is Thursday, 17 May 2018 at 9:00 a.m. AEST). The meeting will […]
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of its investigational drug, mavacamten. MyoKardia recently completed the Phase […]
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
VANCOUVER, May 10, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has received written notification (the “Nasdaq Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has […]
Centers for Medicare and Medicaid Services Approves Reimbursement for BioCardia’s CardiAMP Cell Therapy in Pivotal Clinical Trial Studying Second Indication in Chronic Myocardial Ischemia
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved national reimbursement coverage for the CardiAMP Chronic Myocardial Ischemia Trial. “We are thankful for the CMS decision to […]
Impulse Dynamics Publishes FIX-HF-5C Clinical Trial Results
ORANGEBURG, New York, May 10, 2018 /PRNewswire/ —Impulse Dynamics(USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of Internal Medicine and Director, Division of Cardiovascular Medicine, The Ohio State University Wexner […]



